ReviewToxicology and applied pharmacology2016
Enzymatic oxidative biodegradation of nanoparticles: Mechanisms, significance and applications.
Review in Toxicology and applied pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Advancements in delivery systems for in vivo chimeric antigen receptor T-cell therapy in urological diseases.Current urology · 2026Review
- Article
- Nanodiamonds Co-Localize withPharmaceutics · 2026Article
- Stimuli-Responsive Carbon Nanotubes for On-Demand Cancer Therapy: A Review.AAPS PharmSciTech · 2026Review
- Hydrolytically Stable Cationic Bis-MPA Dendrimers as Efficient Transfectants for Glioblastoma Cells and Primary Astrocytes.Biomacromolecules · 2026Article
- Biocompatibility Research of Magnetosomes Synthesized byInternational journal of molecular sciences · 2025Article
- Inorganic Nanoparticles Containing Plant-Derived Compounds for Kidney Treatment.Bioinorganic chemistry and applications · 2025Review
- Myeloperoxidase enzyme-catalyzed breakdown of zero-dimension carbon quantum dots.Frontiers in medical technology · 2024Article
- Neuroinflammation in the Evolution of Motor Function in Stroke and Trauma Patients: Treatment and Potential Biomarkers.Current issues in molecular biology · 2023Review
- Current Principles, Challenges, and New Metrics in pH-Responsive Drug Delivery Systems for Systemic Cancer Therapy.Pharmaceutics · 2023Review
- Biogenic Selenium Nanoparticles in Biomedical Sciences: Properties, Current Trends, Novel Opportunities and Emerging Challenges in Theranostic Nanomedicine.Nanomaterials (Basel, Switzerland) · 2023Review
- Graphene Oxide Functionalized Gelatin Methacryloyl Microgel for Enhanced Biomimetic Mineralization and in situ Bone Repair.International journal of nanomedicine · 2023Article
- Novel Combination Therapy for Triple-Negative Breast Cancer based on an Intelligent Hollow Carbon Sphere.Research (Washington, D.C.) · 2023Article
- Colloidal Behavior and Biodegradation of Engineered Carbon-Based Nanomaterials in Aquatic Environment.Nanomaterials (Basel, Switzerland) · 2022Review
- Toxicokinetics, dose-response, and risk assessment of nanomaterials: Methodology, challenges, and future perspectives.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Nitrogen-Doped Carbon Nanotube Cups for Cancer Therapy.ACS applied nano materials · 2022Article
- Enzymatic and Cellular Degradation of Carbon-Based Biconcave Nanodisks.Micromachines · 2022Article
- Detection of HOCl-driven degradation of the pericardium scaffolds by label-free multiphoton fluorescence lifetime imaging.Scientific reports · 2022Article
- Coronavirus and Carbon Nanotubes: Seeking Immunological Relationships to Discover Immunotherapeutic Possibilities.International journal of nanomedicine · 2022Review
- Atypical Renal Clearance of Nanoparticles Larger Than the Kidney Filtration Threshold.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Biopersistence of carbon nanotubes, graphene oxide (GO) and several other types of carbonaceous nanomaterials is an essential determinant of their health effects. Successful biodegradation is one of the major factors defining the life span and biological responses to nanoparticles. Here, we review the role and contribution of different oxidative enzymes of inflammatory cells - myeloperoxidase, eosinophil peroxidase, lactoperoxidase, hemoglobin, and xanthine oxidase - to the reactions of nanoparticle biodegradation. We further focus on interactions of nanomaterials with hemoproteins dependent on the specific features of their physico-chemical and structural characteristics. Mechanistically, we highlight the significance of immobilized peroxidase reactive intermediates vs diffusible small molecule oxidants (hypochlorous and hypobromous acids) for the overall oxidative biodegradation process in neutrophils and eosinophils. We also accentuate the importance of peroxynitrite-driven pathways realized in macrophages via the engagement of NADPH oxidase- and NO synthase-triggered oxidative mechanisms. We consider possible involvement of oxidative machinery of other professional phagocytes such as microglial cells, myeloid-derived suppressor cells, in the context of biodegradation relevant to targeted drug delivery. We evaluate the importance of genetic factors and their manipulations for the enzymatic biodegradation in vivo. Finally, we emphasize a novel type of biodegradation realized via the activation of the "dormant" peroxidase activity of hemoproteins by the nano-surface. This is exemplified by the binding of GO to cyt c causing the unfolding and 'unmasking' of the peroxidase activity of the latter. We conclude with the strategies leading to safe by design carbonaceous nanoparticles with optimized characteristics for mechanism-based targeted delivery and regulatable life-span of drugs in circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.